Screener
Gyre Therapeutics, Inc. GYRE Cash Flow Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| -$2.48M-129% | -$22.99M— | -$9.86M-364% | —— | $8.54M+199% | ||
| $467K+66.2% | $1.48M+47.0% | $672K+25.6% | $656K+42.3% | $281K-36.9% | ||
| $1.73M+181% | $2.08M+44.5% | $2.58M+409% | $4.6M+711% | $617K+160% | ||
| -$3.98M-128% | -$16.73M-124% | $3.18M+2,565% | —— | $14.24M— | ||
| $979K+66.2% | $262K-21.8% | $178K+45.9% | $144K— | $589K-15.0% | ||
| $1.73M+131% | $9.76M+621% | -$3.06M-255% | —— | -$5.64M-136% | ||
| $221K-91.1% | —— | $21K-98.4% | $318K-67.0% | $2.47M+663% | ||
| -$1.64M-115% | -$6.34M-145% | $431K-86.7% | —— | $11.27M+4,980% | ||
| -$4.96M-136% | -$16.99M-118% | $3M+1,296% | -$5.77M-114% | $13.65M— |
FAQ
- What is Gyre Therapeutics, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was -$24.7M over the trailing twelve months, down 953.5% year over year.
- Where does Gyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
